Artículos por temáticas

Pathogenesis-targeted, disease-modifying therapies in Parkinson disease.

AlDakheel A, Kalia LV, Lang AE.

Neurotherapeutics. 2014 Jan;11(1):6-23. doi: 10.1007/s13311-013-0218-1. Review.

Lack of association of morphologic and functional retinal changes with motor and non-motor symptoms severity in Parkinson’s disease.

Cubo E, López Peña MJ, Diez-Feijo Varela E, Pérez Gil O, Garcia Gutierrez P, Araus González E, Prieto Tedejo R, Mariscal Pérez N, Armesto D.

J Neural Transm (Vienna). 2014 Feb;121(2):139-45.

Taste performance in Parkinson’s disease.

Cecchini MP, Osculati F, Ottaviani S, Boschi F, Fasano A, Tinazzi M.

J Neural Transm (Vienna). 2014 Feb;121(2):119-22.

Does Parkinson's disease and type-2 diabetes mellitus present common pathophysiological mechanisms and treatments?

Lima MM, Targa AD, Noseda AC, Rodrigues LS, Delattre AM, dos Santos FV, Fortes MH, Maturana MJ, Ferraz AC.

CNS Neurol Disord Drug Targets. 2014 Apr;13(3):418-28. Review.

Pharmacological prolyl hydroxylase domain inhibition as a therapeutic target for Parkinson's disease.

Rajagopalan S, Chinta SJ, Andersen JK.

CNS Neurol Disord Drug Targets. 2014 Feb;13(1):120-5.

Cerebrovascular profile assessment in Parkinson's disease patients.

Perju-Dumbravă L, Muntean ML, Muresanu DF.

CNS Neurol Disord Drug Targets. 2014;13(4):712-7.

Deep brain stimulation may improve quality of life in people with Parkinson's disease without affecting caregiver burden.

Oyama G, Okun MS, Schmidt P, Tröster AI, Nutt J, Go CL, Foote KD, Malaty IA; NPF-QII Investigators..

Neuromodulation. 2014 Feb;17(2):126-32.

Effects of 24 wk of treadmill training on gait performance in Parkinson's disease.

Nadeau A, Pourcher E, Corbeil P.

Med Sci Sports Exerc. 2014 Apr;46(4):645-55. doi: 10.1249/MSS.0000000000000144.

Identification of three novel LRRK2 mutations associated with Parkinson's disease in a Calabrian population.

Anfossi M, Colao R, Gallo M, Bernardi L, Conidi ME, Frangipane F, Vasso F, Puccio G, Clodomiro A, Mirabelli M, Curcio SA, Torchia G, Smirne N, Di Lorenzo R, Maletta R, Bruni AC.

J Alzheimers Dis. 2014;38(2):351-7. doi: 10.3233/JAD-130689.

Signaling pathways involved in 1-octen-3-ol-mediated neurotoxicity in Drosophila melanogaster: implication in Parkinson’s disease.

Inamdar AA, Masurekar P, Hossain M, Richardson JR, Bennett JW.

Neurotox Res. 2014 Feb;25(2):183-91. Erratum in: Neurotox Res. 2014 Feb;25(2):192.

3,4-dihydroxybenzalacetone protects against Parkinson's disease-related neurotoxin 6-OHDA through Akt/Nrf2/glutathione pathway.

Gunjima K, Tomiyama R, Takakura K, Yamada T, Hashida K, Nakamura Y, Konishi T, Matsugo S, Hori O.

J Cell Biochem. 2014 Jan;115(1):151-60. doi: 10.1002/jcb.24643.

Levodopa inhibits habit-learning in Parkinson’s disease.

Fuhrer H, Kupsch A, Hälbig TD, Kopp UA, Scherer P, Gruber D.

J Neural Transm (Vienna). 2014 Feb;121(2):147-51.

Application of proton magnetic resonance spectroscopy on substantia nigra metabolites in Parkinson's disease.

Zhou B, Yuan F, He Z, Tan C.

Brain Imaging Behav. 2014 Mar;8(1):97-101. doi: 10.1007/s11682-013-9251-2.

Using cerebrospinal fluid marker profiles in clinical diagnosis of dementia with Lewy bodies, Parkinson's disease, and Alzheimer's disease.

Kaerst L, Kuhlmann A, Wedekind D, Stoeck K, Lange P, Zerr I.

J Alzheimers Dis. 2014;38(1):63-73. doi: 10.3233/JAD-130995.

Fasciculation and elongation protein zeta-1 (FEZ1) expression in reactive astrocytes in a rat model of Parkinson's disease.

Sun YY, Zhang Y, Sun XP, Liu TY, Liu ZH, Chen G, Xia CL.

Neuropathol Appl Neurobiol. 2014 Feb;40(2):164-76. doi: 10.1111/nan.12077.